874 — Guangzhou Baiyunshan Pharmaceutical Holdings Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro Cap

Annual income statement for Guangzhou Baiyunshan Pharmaceutical Holdings Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	C2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	61,674	69,014	70,788	75,515	74,993
Cost of Revenue
Gross Profit	10,416	13,221	13,272	14,185	12,499
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	58,004	64,231	65,718	70,393	71,399
Operating Profit	3,670	4,783	5,070	5,122	3,594
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	3,739	4,723	5,043	5,110	3,608
Provision for Income Taxes
Net Income After Taxes	3,092	3,969	4,253	4,259	3,001
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,915	3,720	3,967	4,056	2,835
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,915	3,720	3,967	4,056	2,835
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.8	2.27	2.43	2.48	1.93
Dividends per Share